Alimera Sciences to Report Second Quarter 2018 Results July 30, 2018
PR Newswire
ATLANTA, July 18, 2018
ATLANTA, July 18, 2018 /PRNewswire/ -- Alimera Sciences ALIM, a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the second quarter ended June 30, 2018, after the close of the financial markets on Monday, July 30, 2018.
An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. The call will be held at 9:00 AM ET, on Tuesday, July 31, 2018. Please refer to the information below for conference call dial-in information and webcast registration.
Conference Details
Conference date: Tuesday July 31, 2018 9:00 AM ET
Conference dial-in: 877.269.7756
International dial-in: 201.689.7817
Conference Call Name: Alimera Sciences Second Quarter 2018 Results Call
Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website, www.alimerasciences.com, under "Investor Relations."
About Alimera Sciences
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in Alimera's product portfolio. For more information, please visit www.alimerasciences.com.
For press inquiries: Katie Brazel for Alimera Sciences 404-317-8361 |
For investor inquiries: CG Capital for Alimera Sciences 877-889-1972 |
View original content with multimedia:http://www.prnewswire.com/news-releases/alimera-sciences-to-report-second-quarter-2018-results-july-30-2018-300682692.html
SOURCE Alimera Sciences, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.